Navigation Links
Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting

ed skin rash. Loss of EGFR signaling has been hypothesized as a mechanism of skin toxicity in patients receiving EGFRIs. In vitro studies have suggested that topically-applied Menadione may restore EGFR signaling, specifically in the skin of patients treated systemically with EGFRIs. Currently, there are no FDA-approved products or therapies available to treat these skin toxicities. Following the completion of non-clinical studies with Menadione, Hana plans to submit an Investigational New Drug application by the end of 2007.

About Marqibo(r) (vincristine sulfate injection, OPTISOME(tm))

Marqibo, a novel, targeted, Optisomal formulation of vincristine, has shown promising anti-cancer activity in patients with non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL) clinical trials. Vincristine, a microtubule inhibitor, is FDA-approved as a single agent and in combination regimens for the treatment of hematologic malignancies such as lymphomas and leukemias. Vincristine kills cancer cells when they enter a very specific point in the cell cycle -- and its efficacy is concentration- and time-dependent. Marqibo extends circulation time of vincristine in the bloodstream and subsequently increases targeting of the drug to the tumor site. Marqibo allows for a significant increase in the dose of the active ingredient as opposed to the dose of the conventional vincristine. The FDA granted Marqibo Orphan Drug Designation for the treatment of adult ALL.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Bi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
2. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
3. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
(Date:6/1/2015)... -- The Middle Eastern MRI systems market is fast growing. ... all domains of medicine like cardiology, neurology and orthopedics. It ... precision and is as safer tool as it does not ... on equipment into Open system, closed system and straight or ... demand as it is preferred over that currently common closed ...
(Date:6/1/2015)... June 1, 2015 Novel t ... drive growth , says   GBI Research ... (NSCLC) treatment market will be driven primarily by the introduction ... treatment settings, which either replace or combine with generic chemotherapies. ... Non-Small Cell Lung Cancer Market to 2020 - ...
(Date:6/1/2015)... , June 1, 2015 Symbiotix Biotherapies, ... $2.3 million Phase 2 Small Business Technology Transfer (STTR) ... National Institute of Allergy and Infectious Diseases (NIAID). The ... developing a novel class of molecular therapeutics from ... clinical candidate, Polysaccharide A (PSA), is the first molecule ...
Breaking Medicine Technology:Middle East MRI Market - Growth, Trends And Forecasts (2014 - 2019) 2Middle East MRI Market - Growth, Trends And Forecasts (2014 - 2019) 3New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3Symbiotix Biotherapies Announces $2.3 Million Award from NIH's National Institute of Allergy and Infectious Diseases (NIAID) 2
... BabyPing will unveil a new high ... - CES - this week. The new BabyPing high security ... their infant on iPhone, iPad or iPod Touch through cutting edge ... truly reassuring alternative to old-style monitors by using the latest in ...
... 2012 /PRNewswire-Asia/ -- The Ministry of Health and Welfare and ... referred from the Health Authority-Abu Dhabi (HAAD) arrived in South ... The Korean government arranged for domestic hospitals to sign ... Dhabi when HAAD Chairman Mohammed Sultan Al Hameli and CEO ...
Cached Medicine Technology:BabyPing Wi-Fi Baby Monitor for iOS Debuts at CES - the Next Generation of Baby Monitor is Here 2First Patient from Abu Dhabi Arrives in South Korea for Medical Treatment 2
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Kathy Everette-Gaines as a 2015-2016 inductee into ... is recognized with this prestigious distinction for leadership ... organization exclusively for professional women, boasting more than ... , “I’m pleased to welcome Kathy into this ...
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Lenita F. Cornett, DSL, LSSBB (C), First ... into its VIP Woman of the Year Circle. She ... the military. NAPW is the nation's leading networking organization ... and over 200 operating Local Chapters. , “I'm pleased ...
(Date:6/1/2015)... 01, 2015 Carson Energy also announced ... investors IRA transactions. AdvantaIRA Trust, LLC is the country’s ... ability to fund positions using IRA’s does 2 things:, ... a project, even if there current cash position will ... funding source for Carson and their investors to be ...
(Date:6/1/2015)... June 01, 2015 The federal court ... has amended the Case Management Order governing case selection ... The Amended Order which was issued in the ... 29, 2015, directs the parties to submit a Proposed ... 2015 that outlines parameters and the process for selecting ...
(Date:6/1/2015)... Atagi Plastic Surgery and Skin Aesthetics is ... Ultherapy® Ultra Treatment Provider by Ulthera, the manufacturer ... one of only six practices in Colorado to be ... , Atagi Plastic Surgery and Skin Aesthetics’ experience and ... the practice to earn the distinction of being named ...
Breaking Medicine News(10 mins):Health News:The National Association of Professional Women Inducts Kathy Everette-Gaines, Community Relations Coordinator, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 4Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2
... Laboratories, Inc. (Nasdaq: IDXX ), today reported that ... compared to $249.1 million for the first quarter of 2008. ... impact of changes in foreign currency exchange rates and the ... 2009, due to the divestiture in the fourth quarter of ...
... positive and HIV negative patients have comparable survival rates ... at EASL 2009, the Annual Meeting of the European ... , The study results showed no difference in survival ... and HIV positive patients (86.5% and 74% versus 87.1% ...
... recent two-year study show promising long-term survival benefits for patients living ... the small blood vessels in the lungs become scarred and narrowed ... high levels, putting a major strain on the heart. , ... ...
... forth by reputable organizations like the American Heart Association and the ... the most effective and have the least amount of side effects. ... determine if their doctor is following these guidelines or not. ... ...
... ad agency, Preston Kelly, to launch national marketing campaign to raise ... ... Minneapolis, MN (PRWEB) April 24, 2009 -- The National Marrow Donor ... joined forces to launch Be The MatchSM--the effort designed to increase ...
... EHRtv on EHR implementation and the state of Healtcare IT in ... ... 24, 2009 -- EHRtv.com, the newly launched website for Comprehensive Video ... interview Former Representative Richard Gephardt during the Recent HIMSS09 Health IT ...
Cached Medicine News:Health News:IDEXX Laboratories Announces First Quarter Results 2Health News:IDEXX Laboratories Announces First Quarter Results 3Health News:IDEXX Laboratories Announces First Quarter Results 4Health News:IDEXX Laboratories Announces First Quarter Results 5Health News:IDEXX Laboratories Announces First Quarter Results 6Health News:IDEXX Laboratories Announces First Quarter Results 7Health News:IDEXX Laboratories Announces First Quarter Results 8Health News:IDEXX Laboratories Announces First Quarter Results 9Health News:IDEXX Laboratories Announces First Quarter Results 10Health News:IDEXX Laboratories Announces First Quarter Results 11Health News:IDEXX Laboratories Announces First Quarter Results 12Health News:IDEXX Laboratories Announces First Quarter Results 13Health News:IDEXX Laboratories Announces First Quarter Results 14Health News:IDEXX Laboratories Announces First Quarter Results 15Health News:IDEXX Laboratories Announces First Quarter Results 16Health News:IDEXX Laboratories Announces First Quarter Results 17Health News:IDEXX Laboratories Announces First Quarter Results 18Health News:HIV positive and HIV negative patients have similar survival rates following liver transplant 2Health News:New Study Shows Long-Term Benefits for Patients with Pulmonary Arterial Hypertension 2Health News:New Study Shows Long-Term Benefits for Patients with Pulmonary Arterial Hypertension 3Health News:An Innovative New Book Helps Consumers Find Out if Their Doctors are Following Official Treatment Guidelines 2Health News:Be The MatchSM Brand Campaign Launches 2Health News:Be The MatchSM Brand Campaign Launches 3Health News:Representative Richard Gephardt Sits Down With EHRtv.com 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Cottle Tenaculum Skin Hook. 5 1/2" small, shallow curve....
Medicine Products: